Daniel Gusenleitner
Daniel Gusenleitner
Novartis Institutes for Biomedical Research
Verified email at novartis.com
Cited by
Cited by
Targetable genetic features of primary testicular and primary central nervous system lymphomas
B Chapuy, MGM Roemer, C Stewart, Y Tan, RP Abo, L Zhang, AJ Dunford, ...
Blood, The Journal of the American Society of Hematology 127 (7), 869-881, 2016
MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
SJ Rodig, D Gusenleitner, DG Jackson, E Gjini, A Giobbie-Hurder, C Jin, ...
Science translational medicine 10 (450), 2018
Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma
CD Carey, D Gusenleitner, M Lipschitz, MGM Roemer, EC Stack, E Gjini, ...
Blood 130 (22), 2420-2430, 2017
GeneSigDB: a manually curated database and resource for analysis of gene expression signatures
AC Culhane, MS Schröder, R Sultana, SC Picard, EN Martinelli, C Kelly, ...
Nucleic acids research 40 (D1), D1060-D1066, 2012
Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
PB Subrahmanyam, Z Dong, D Gusenleitner, A Giobbie-Hurder, ...
Journal for immunotherapy of cancer 6 (1), 1-14, 2018
An aryl hydrocarbon receptor-mediated amplification loop that enforces cell migration in ER−/PR−/Her2− human breast cancer cells
O Novikov, Z Wang, EA Stanford, AJ Parks, A Ramirez-Cardenas, ...
Molecular pharmacology 90 (5), 674-688, 2016
Cancer-germline antigen expression discriminates clinical outcome to CTLA-4 blockade
SA Shukla, P Bachireddy, B Schilling, C Galonska, Q Zhan, C Bango, ...
Cell 173 (3), 624-633. e8, 2018
Genomic models of short-term exposure accurately predict long-term chemical carcinogenicity and identify putative mechanisms of action
D Gusenleitner, SS Auerbach, T Melia, HF Gómez, DH Sherr, S Monti
PLoS One 9 (7), e102579, 2014
Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease
B Chapuy, H Cheng, A Watahiki, MD Ducar, Y Tan, L Chen, MGM Roemer, ...
Blood, The Journal of the American Society of Hematology 127 (18), 2203-2213, 2016
iBBiG: iterative binary bi-clustering of gene sets
D Gusenleitner, EA Howe, S Bentink, J Quackenbush, AC Culhane
Bioinformatics 28 (19), 2484-2492, 2012
ASSIGN: context-specific genomic profiling of multiple heterogeneous biological pathways
Y Shen, M Rahman, SR Piccolo, D Gusenleitner, NN El-Chaar, L Cheng, ...
Bioinformatics 31 (11), 1745-1753, 2015
RamiGO: an R/Bioconductor package providing an AmiGO visualize interface
MS Schröder, D Gusenleitner, J Quackenbush, AC Culhane, ...
Bioinformatics 29 (5), 666-668, 2013
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised …
R Dummer, JC Brase, J Garrett, CD Campbell, E Gasal, M Squires, ...
The Lancet Oncology 21 (3), 358-372, 2020
Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens
CD Carey, D Gusenleitner, B Chapuy, AE Kovach, MJ Kluk, HH Sun, ...
The Journal of Molecular Diagnostics 17 (1), 19-30, 2015
GCOD-GeneChip Oncology Database
F Liu, J White, C Antonescu, J Quackenbush
BMC bioinformatics 12 (1), 46, 2011
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i
R Dummer, C Lebbé, V Atkinson, M Mandalà, PD Nathan, A Arance, ...
Nature Medicine 26 (10), 1557-1563, 2020
Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma
GK Griffin, JL Weirather, MGM Roemer, M Lipschitz, A Kelley, PH Chen, ...
Blood, The Journal of the American Society of Hematology 137 (10), 1353-1364, 2021
Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities
EA Morgan, MP Sweeney, T Tomoka, N Kopp, D Gusenleitner, RA Redd, ...
Blood advances 1 (1), 84-92, 2016
Actionable genetic features of primary testicular and primary central nervous system lymphomas
B Chapuy, MGM Roemer, Y Tan, C Stewart, L Zhang, AJ Dunford, ...
Blood, The Journal of the American Society of Hematology 124 (21), 74-74, 2014
Effect of first-line spartalizumab+ dabrafenib+ trametinib on immunosuppressive features detected in peripheral blood and clinical outcome in patients (pts) with advanced BRAF …
R Dummer, K Biette, D Gusenleitner, R Ramesh, C Lebbe, V Atkinson, ...
Journal of Clinical Oncology 38 (15_suppl), 10034-10034, 2020
The system can't perform the operation now. Try again later.
Articles 1–20